<DOC>
	<DOCNO>NCT02420392</DOCNO>
	<brief_summary>To investigate effect dapagliflozin incretin sensitivity pancreatic beta cell .</brief_summary>
	<brief_title>Effects Dapagliflozin Incretin Sensitivity Pancreatic Beta Cell</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<criteria>Type 2 diabetes dapagliflozin arm Normal glucose tolerance ( fast plasma glucose &lt; 100 mgd/l , HbA1c &lt; 6.0 % ) normal glucose tolerance arm Age 18 75 year BMI &lt; 35 kg/m2 For type 2 diabetes patient , least 3 month treatment period HbA1c 7.5 11.0 % treatment lifestyle modification and/or metformin sulfonylurea Who allergic dapagliflozin Type 1 diabetes Patients history diabetic ketoacidosis Reduced renal function ( eGFR &lt; 60ml/min/1.73m2 ) Taking loop diuretic dehydrate patient History hypotension take hypertensive medication Diagnosed heart failure Diagnosed cerebral infarction Taking insulin , DPP4 inhibitor , GLP1 analogue , pioglitazone , alphaglucosidase inhibitor Above upper limit normal hematocrit range ( male 3952 % , female 3648 % ) Pregnant breastfeed woman History recurrent genitourinary infection AST/ALT two fold increase normal upper limit Hemolytic disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>